Marvanová M, Lakso M, Pirhonen J, Nawa H, Wong G, Castrén E
A. I. Virtanen Institute, University of Kuopio, Kuopio, 70211, Finland.
Mol Cell Neurosci. 2001 Sep;18(3):247-58. doi: 10.1006/mcne.2001.1027.
Memantine is a medium-affinity uncompetitive N-methyl-d-aspartate receptor antagonist and has been clinically used as a neuroprotective agent to treat Alzheimer's and Parkinson's diseases. We have examined the effect of memantine (ip 5-50 mg/kg; 4 h) on the expression of brain-derived neurotrophic factor (BDNF) and trkB receptor mRNAs in rat brain by in situ hybridization. Memantine at a clinically relevant dose markedly increased BDNF mRNA levels in the limbic cortex, and this effect was more widespread and pronounced at higher doses. Effects of memantine on BDNF mRNA were also reflected in changes in BDNF protein levels. Moreover, memantine induced isoforms of the BDNF receptor trkB. Taken together, these data suggest that the neuroprotective properties of memantine could be mediated by the increased endogenous production of BDNF in the brain. These findings may open up new possibilities of pharmacologically regulating the expression of neurotrophic factors in the brain.
美金刚是一种中等亲和力的非竞争性N-甲基-D-天冬氨酸受体拮抗剂,已在临床上用作神经保护剂来治疗阿尔茨海默病和帕金森病。我们通过原位杂交研究了美金刚(腹腔注射5-50mg/kg;4小时)对大鼠脑源性神经营养因子(BDNF)和trkB受体mRNA表达的影响。临床相关剂量的美金刚显著增加了边缘皮质中BDNF mRNA的水平,且在较高剂量时这种作用更广泛、更明显。美金刚对BDNF mRNA的影响也反映在BDNF蛋白水平的变化上。此外,美金刚诱导了BDNF受体trkB的亚型。综上所述,这些数据表明美金刚的神经保护特性可能是由大脑中BDNF内源性产生增加介导的。这些发现可能为药理学调节大脑中神经营养因子的表达开辟新的可能性。